VivoSeq
Oncology

Leukemia Acute Myeloid

3

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

Leukemia Acute Myeloid is an early-stage landscape with 3 programs across 3 companies. The most active players are Karuna Therapeutics, Inc., a Bristol Myers Squibb company, AbbVie, Syndax Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

6/100

Mech. Concentration

33/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 2AbbVie logo

AbbVie

1 program

Phase 2S

Syndax Pharmaceuticals

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 23

Azacitidine

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Venetoclax

AbbVie

Revumenib

Syndax Pharmaceuticals

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

1

clinical trials

Not yet recruiting1 · 100%

Clinical Trials

Trial Activity

Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML
Not yet recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT07605949·88 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)